Latest Period
Q4 2025
Security Snapshot
BICYCLE THERAPEUTICS PLC - Common Stock (BCYC) Institutional Ownership
CUSIP: 088786108
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
108
Shares (Excl. Options)
39,173,179
Price
$7.08
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock
- Symbol
- BCYC on Nasdaq
- Shares outstanding
- 49,984,905
- Price per share
- $4.98
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 39,173,179
- Total reported value
- $277,661,671
- % of total 13F portfolios
- 0%
- Share change
- +532,216
- Value change
- +$3,442,632
- Number of holders
- 108
- Price from insider filings
- $4.98
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- BCYC - BICYCLE THERAPEUTICS PLC - Common Stock is tracked under CUSIP 088786108.
- 108 institutions reported positions in Q4 2025.
- 5 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 108 to 12 between Q4 2025 and Q1 2026.
- Reported value moved from $277,661,671 to $1,275,789.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 108 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 088786108?
CUSIP 088786108 identifies BCYC - BICYCLE THERAPEUTICS PLC - Common Stock in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 088786108:
Significant Owners of BICYCLE THERAPEUTICS PLC - Common Stock (BCYC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities Fund II Cooperatief U.A. | 7.3% | $28,343,629 | 3,452,330 | Forbion Growth Opportunities Fund II Cooperatief U.A. | 21 Nov 2024 | |||
| ARMISTICE CAPITAL, LLC | 6.5% | +15% | $21,292,880 | +$3,711,120 | 3,236,000 | +21% | Armistice Capital, LLC | 31 Dec 2025 |
| Invus Global Management, LLC | 6.3% | $17,729,146 | 3,149,049 | Raymond Debbane | 25 Feb 2026 | |||
| Point72 Asset Management, L.P. | 3.9% | -49% | $14,882,536 | -$15,032,008 | 1,860,317 | -50% | Point72 Asset Management, L.P. | 30 Jun 2025 |
| Deep Track Capital, LP | 2.4% | -54% | $9,625,952 | -$12,943,416 | 1,203,244 | -57% | Deep Track Capital, LP | 30 Jun 2025 |
As of 31 Dec 2025, 108 institutional investors reported holding 39,173,179 shares of BICYCLE THERAPEUTICS PLC - Common Stock (BCYC). This represents 78% of the company’s total 49,984,905 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of BICYCLE THERAPEUTICS PLC - Common Stock (BCYC) together control 72% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | 22% | 10,885,357 | 0% | 0.45% | $77,068,328 |
| FCPM III SERVICES B.V. | 6.9% | 3,468,430 | +0.47% | 3.2% | $24,556,484 |
| ARMISTICE CAPITAL, LLC | 6.5% | 3,236,000 | +8.7% | 0.56% | $22,910,880 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 6% | 3,016,026 | +2.2% | 0.09% | $21,353,464 |
| Siren, L.L.C. | 4% | 2,012,752 | 0% | 0.43% | $14,250,284 |
| ACADIAN ASSET MANAGEMENT LLC | 3.3% | 1,671,258 | +27% | 0.02% | $11,806,000 |
| Long Focus Capital Management, LLC | 3.3% | 1,633,091 | +15% | 0.59% | $11,562,284 |
| GSK plc | 3.1% | 1,529,561 | 0% | 1.4% | $10,829,292 |
| Candriam S.C.A. | 2.4% | 1,192,279 | +1.7% | 0.04% | $8,441,695 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.3% | 1,171,787 | -15% | 0% | $8,297,000 |
| PRINCIPAL FINANCIAL GROUP INC | 2.3% | 1,148,272 | -0.01% | 0% | $8,129,766 |
| SCHRODER INVESTMENT MANAGEMENT GROUP | 1.2% | 584,770 | 0% | $3,976,436 | |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.1% | 568,225 | 0% | $4,023,000 | |
| RENAISSANCE TECHNOLOGIES LLC | 1.1% | 566,600 | +9.2% | 0.01% | $4,011,528 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | 0.95% | 476,976 | 0% | 0.02% | $3,376,990 |
| MORGAN STANLEY | 0.93% | 465,222 | -43% | 0% | $3,293,773 |
| Birchview Capital, LP | 0.93% | 462,700 | +200% | 1.9% | $3,275,916 |
| BlackRock, Inc. | 0.67% | 332,889 | +18% | 0% | $2,356,854 |
| MILLENNIUM MANAGEMENT LLC | 0.65% | 326,626 | -69% | 0% | $2,312,512 |
| Jefferies Financial Group Inc. | 0.59% | 297,247 | -26% | 0.02% | $2,104,509 |
| MOORE CAPITAL MANAGEMENT, LP | 0.55% | 275,000 | +120% | 0.04% | $1,947,000 |
| CITADEL ADVISORS LLC | 0.54% | 271,383 | +44% | 0% | $1,921,391 |
| Palo Alto Investors LP | 0.44% | 221,071 | 0% | 0.22% | $1,565,183 |
| PINNACLE ASSOCIATES LTD | 0.38% | 190,480 | -3.1% | 0.02% | $1,348,598 |
| PLATINUM INVESTMENT MANAGEMENT LTD | 0.37% | 184,603 | 0% | 0.3% | $1,306,989 |
Institutional Holders of BICYCLE THERAPEUTICS PLC - Common Stock (BCYC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 274,969 | $1,275,789 | -$9,345,796 | $4.64 | 12 |
| 2025 Q4 | 39,173,179 | $277,661,671 | +$3,442,632 | $7.08 | 108 |
| 2025 Q3 | 36,906,185 | $285,619,779 | -$29,768,237 | $7.74 | 99 |
| 2025 Q2 | 41,200,406 | $286,338,478 | -$7,404,258 | $6.95 | 110 |
| 2025 Q1 | 41,735,285 | $354,350,748 | -$8,366,393 | $8.49 | 95 |
| 2024 Q4 | 41,890,221 | $586,472,317 | -$21,543,705 | $14.00 | 96 |
| 2024 Q3 | 40,439,351 | $915,266,321 | +$21,080,974 | $22.63 | 104 |
| 2024 Q2 | 39,722,044 | $803,959,492 | +$167,237,644 | $20.24 | 105 |
| 2024 Q1 | 30,475,266 | $758,677,656 | +$6,974,793 | $24.90 | 93 |
| 2023 Q4 | 31,374,408 | $567,252,558 | -$28,664,876 | $18.08 | 98 |
| 2023 Q3 | 32,418,922 | $651,281,538 | +$165,201,151 | $20.09 | 101 |
| 2023 Q2 | 24,236,173 | $618,449,426 | +$18,484,148 | $25.52 | 84 |
| 2023 Q1 | 23,558,818 | $498,895,905 | -$47,151,037 | $21.27 | 89 |
| 2022 Q4 | 23,577,228 | $697,847,861 | +$39,624,167 | $29.60 | 87 |
| 2022 Q3 | 23,196,999 | $539,598,338 | +$13,911,506 | $23.26 | 77 |
| 2022 Q2 | 22,709,672 | $381,075,755 | -$69,885,312 | $16.78 | 78 |
| 2022 Q1 | 20,168,148 | $884,247,452 | -$137,175,184 | $43.88 | 100 |
| 2021 Q4 | 21,550,279 | $1,311,636,981 | +$387,558,387 | $60.87 | 98 |
| 2021 Q3 | 14,210,499 | $591,072,741 | +$80,484,868 | $41.59 | 67 |
| 2021 Q2 | 12,412,613 | $376,901,461 | +$30,169,498 | $30.36 | 53 |
| 2021 Q1 | 11,420,830 | $341,203,000 | +$123,064,104 | $29.87 | 39 |
| 2020 Q4 | 7,328,435 | $131,544,000 | -$3,975,466 | $17.95 | 27 |
| 2020 Q3 | 7,550,163 | $143,830,000 | +$24,085,212 | $19.05 | 18 |
| 2020 Q2 | 6,287,737 | $98,861,000 | +$4,298,929 | $15.74 | 15 |
| 2020 Q1 | 5,977,254 | $81,901,000 | +$1,078,206 | $13.65 | 12 |
| 2019 Q4 | 5,901,993 | $55,657,000 | -$6,870,216 | $9.43 | 8 |
| 2019 Q3 | 6,446,149 | $73,420,000 | -$1,907,302 | $11.39 | 11 |
| 2019 Q2 | 6,635,216 | $66,751,000 | +$66,751,000 | $10.06 | 14 |